Registered number: 08239097
Charity number: 1149638

THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES

(A Company Limited by Guarantee)

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES
(A Company Limited by Guarantee)

CONTENTS

	Page
Reference and Administrative Details of the Company, its Trustees and Advisers	1 - 2
Trustees' Report	3 - 18
Trustees' Responsibilities Statement	19
Independent Auditors' Report on the Financial Statements	20 - 23
Statement of Financial Activities	24
Balance Sheet	25
Statement of Cash Flows	26
Notes to the Financial Statements	27 - 46

THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES
(A Company Limited by Guarantee)

REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 DECEMBER 2025

Trustees

P Laidler, Congress Counsellor (appointed 1 January 2020, resigned 31 December 2025)

F Michelangeli, Treasurer (appointed 1 January 2017)

F G Sağin, Chair, Education and Training Committee (appointed 1January 2019)

I Diaz Moreno, Chair, Career of Young Scientist Committee (appointed 1 January 2018)

M De La Rosa, Secretary General (appointed 1 January 2015)

J Dumić, Chair of Integration and Networking Committee (appointed 1 January 2017, resigned 31 December 2025) E Fragkoulis, Chair, Science and Society Committee (appointed 1 January 2017, resigned 31 December 2025)

A Krol, Chair, Excellence Awards and Fellowships Committee (appointed 1 January 2017, resigned 31 December 2025)

J Buchner, Chair, Publications Committee (appointed 1 January 2021)

C Dean, Chair, Working Group on Women in Science (appointed 1 January 2023, resigned 31 December 2025)

M Maccarrone, Chair, Advanced Courses Committee (appointed 1 January 2024)
M Magnani, Vice Chair (appointed 1 January 2025)

R Miggiano, Acting Chair, Careers of Young Scientists Committee (appointed 1 January 2026)

X Coumoul, Chair, Integration and Networking Committee (appointed 1 January 2026)

R Žukiene, Chair, Science and Society Committee (appointed 1 January 2026)

M Soveral, Congress Counsellor (appointed 1 January 2026)

A Ephrussi, Chair, Working Group on Women in Science (appointed 1 January 2025)

Company registered number

08239097

Charity registered number

1149638

Registered office

2d & 2e, St Andrew's House, 59 St Andrew's Street, Cambridge, CB2 3BZ

Company secretary

Professor M De La Rosa

Independent auditors

Hill Wooldridge & Co. Limited, Monument House, 215 Marsh Road, Pinner, HA5 5NE

Bankers

HSBC UK Bank PLC, 1 Corn Market & Church Street, High Wycombe, HP11 2AY

Investment managers

J.P. Morgan Private Bank, 60 Victoria Embankment, London, EC4Y 0JP

Cazenove Capital, 1 London Wall Place, London, EC2Y 5AU

Sarasin & Partners, 50 George Street, London, W1U 7DY

CCLA, 1 Angel Lane, London, EC4R 3AB

PITCH, Property Income Trust for Charities, Swiss Life Asset Managers UK Limited, 55, Wells Street, London W1T 3PT

TRUSTEES' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025

The Trustees present their annual report together with the audited financial statements of the Company for the year 1 January 2025 to 31 December 2025. The Annual Report serves the purposes of both a Trustees' report and a directors' report under company law. The Trustees confirm that the Annual Report and financial statements of the charitable company comply with the current statutory requirements, the requirements of the charitable company's governing document and the provisions of the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2019).

Since the Company qualifies as small under section 382 of the Companies Act 2006, the Strategic Report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 has been omitted.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Constitution

FEBS is registered as a charity (registered charity number 1149638), and is a company limited by guarantee (registered company number 08239097). The Memorandum and Articles of Association by which FEBS is governed can be found here: https://www.febs.org/wp-content/uploads/2025/03/FEBS-Memorandum-and-Articles-of-Association-2025.pdf .

Organisation and membership

FEBS was founded on 1st January 1964 and is a Federation of biochemistry and molecular biology societies. In 2025, its Constituent Societies spanned 39 countries in Europe and neighbouring regions and included 35 Member Societies and 4 Associate Member Societies. The Constituent Societies of the Federation in 2025 are given in Appendix 1, and their membership numbers in Appendix 2 (totalling 23,556 individual members in 2025). (2 societies – Russia and Belarus – had their membership of FEBS suspended following a Council vote in 2022 and they currently remain suspended.)

FEBS is governed by a Council composed of one delegate from each of the Constituent Societies as well as the members of the Executive Committee. FEBS Council meets once a year at the annual FEBS Congress. The Council elects members of the FEBS Executive Committee for three-year terms (except the Chair and Vice-Chair positions), as well as ordinary members of the FEBS Committees and Working Groups (delegated specific areas of FEBS activities) for four-year terms, in a secret ballot. The Vice-Chair of the Executive Committee, who after one year becomes Chair, is appointed by the Society hosting the annual Congress and Council Meeting in the previous year.

Subject to the Council, the administration of the Federation is vested in the FEBS Executive Committee (the 'FEBS Officers'). The Executive Committee consists of the Chairperson, the Vice-Chairperson, the FEBS Secretary General, the FEBS Treasurer, the FEBS Congress Counsellor, and the FEBS Committee and Working Group Chairpersons. With the exception of co-opted Acting Chairpersons (e.g. following resignations prior to Council elections), FEBS Officers are the FEBS charity Trustees and company Directors responsible for the actions of FEBS. The names of the members of the Executive Committee and the names of members of other Committees and Working Groups in 2025, together with dates of appointments and geographical distribution, are set out in Appendix 3.

The FEBS Trustees/Directors are distinguished scientists and (with the exception of the Executive Committee Vice Chair and Chair, as explained above) elected by FEBS Council from nominations put forward by FEBS Constituent Societies. Before formal appointment, newly elected Trustees/Directors sign the Charity Commission's 'Declaration of eligibility for newly appointed Trustees' and are referred to the Charity Commission's guidance on the role of Trustees as well as Companies House information on Director/Secretary roles.

OBJECTIVES AND ACTIVITIES

Objectives

The objectives of FEBS are to contribute to and promote the advancement of research and education for the public benefit in the sciences of biochemistry, molecular biology and related disciplines (but only in so far as such related disciplines are ancillary to the main objective), by all suitable means and in particular by:

- holding and arranging congresses, training and educational courses on matters connected with biochemistry and molecular biology and related disciplines.
- facilitating and supporting the exchange of scientific information between biochemists, molecular biologists and scientists working in related disciplines generally and especially in Europe and other countries of Constituent Societies.
- facilitating and supporting the training of young scientists in research, in the form of fellowships and Excellence Awards; and
- organising the editing and publication of scientific research and educational material in biochemistry and molecular biology and related disciplines.

Activities

The following paragraphs and their associated appendices outline activities in 2025 from the different Committees and Working Groups of FEBS. Extensive information on FEBS work is also available on the FEBS website at www.febs.org and highlights appeared in the issue of FEBS News (pdf magazine) in 2025: https://www.febs.org/news/febs-news-magazine/.

Strategic Priorities 2025 – 2028

FEBS future income faces a less certain future due to open access publishing, uncertainty about the future of academic publishing models and reduced income from our publishing agreement, as well as the current difficult socio-economic circumstances worldwide impacting on our investment returns. There are positive prospects including the scientific community's contribution to the pandemic and opportunities to work more closely with FEBS member societies and other closely related scientific organisations to provide benefit to molecular life sciences in Europe and beyond.

During 2023 and 2024, FEBS undertook a review and formulated its strategic priorities for the next five years, led by the Executive Committee and in consultation with FEBS Council.

The main topics identified during this process were:

- Collaboration and synergy;
- Congress and events;
- Income and diversification; and
- Marketing and promotion.

Following this initial work, necessary updates to FEBS Articles and By Laws were approved by Council, followed by the timeline for the implementation phase of the priorities identified.

Scientific publications

FEBS owns four journals for the publication of research papers, reviews and discussion in the molecular life sciences: *The FEBS Journal, FEBS Letters, Molecular Oncology and FEBS Open Bio*. They are published on behalf of FEBS by Wiley and aim to provide high-quality peer review, fast publication, and a variety of enhanced features for both authors and readers. The journals provide most of the income to fund FEBS' other activities.

The Publications Committee oversees the operation and development of FEBS' journals and in 2025 was under the chairmanship of Johannes Buchner. All four journals are internationally recognised to be of high quality as detailed below. The four journals are fully digital and can be reached through the FEBS Press platform (www.febspress.org).

The FEBS Press journals embrace changing publishing practices and offer simple submission in any format and a smooth publication process, with fair and transparent peer review managed by editorial board members who are experts in the field. Thorough ethics and research integrity checks are run by our experienced editorial staff prior to article publication. All journals now publish peer review reports alongside research articles. Authors of articles rejected by one FEBS Press journal can choose to have their manuscript automatically transferred to another. All journals offer open access options; about 71% of total articles published in 2025 were open access (similar to 2024).

- The FEBS Journal (www.febsjournal.org) publishes high-quality full-length research papers relevant to the molecular, cellular and biochemical life sciences. The journal also publishes a diverse portfolio of commissioned front-half content review and editorial content, including State-of-the-Art Reviews, Commentaries, Discovery-in-Context Reviews, Structural Snapshots, Viewpoints, Words-of-Advice guides and interviews with eminent scientists (In Conversation With ...). Key metrics for 2024 published in 2025: Impact Factor 4.2, CiteScore 13.7. In 2025, the median time from submission to first decision after peer review was 46 days. In 2025, the journal published 379 articles in 24 issues. Authors have the option of publishing their article open access.
- FEBS Letters (www.febsletters.org) publishes research reports (both short reports and full-length articles) that significantly impact and advance knowledge in the molecular biosciences; editorial speed is a key feature of the journal. The journal also publishes a diverse range of Reviews (including In a Nutshell and Perspectives) and other front-half content (Commentaries, Scientists' Forum). Key metrics for 2024 published in 2025: Impact Factor 3, CiteScore 6.1. Median time for submissions to first decision after peer review 30 days. In 2025, the journal published 254 articles in 24 issues. Authors have the option of publishing their article open access.
- Molecular Oncology (www.moloncol.org) publishes high-impact research articles in basic, translational and clinical cancer research. The journal also publishes commissioned reviews and policy papers discussing emerging concepts in cancer research, cancer diagnosis, prevention and care. Key metrics for 2024 published in 2025: Impact factor 4.5, CiteScore 11.4. Median time from submission to first decision after peer review 45 days. In 2025, 238 articles were published in 12 issues. The journal is fully open access.
- FEBS Open Bio (www.febsopenbio.org), publishes research articles, methods and protocols across the molecular and cellular life sciences, with the emphasis on technical and ethical quality rather than subjective judgements of significance. Research articles on Education in the molecular life sciences are published free of charge. Key metrics for 2024 published in 2025: Impact factor 2.3, CiteScore 5.6. Median time from submission to first decision after peer review 36 days. In 2024, 157 articles were published in 12 issues. The journal is fully open access.

Excellence Awards and Fellowships Committee
In 2025, the Chairman of the Excellence Awards and Fellowships Committee was Prof. Alain Krol. This report provides information on the range of applications received for the various categories of Fellowships.

FEBS Excellence Awards
The first call for this new program was made in June 2021 and a call has taken place each subsequent year. This award is intended for early-career scientists who have been established in a salaried capacity in a host institution of a FEBS Constituent Society as a Principal Investigator (PI) for at least one year. The Award is endowed with a €100,000 grant for 3 years to be used exclusively for purchasing consumable/equipment. In 2025, 42 eligible applications were received and 10 were awarded. The second FEBS Excellence Award Meeting took place in Sapanca. Türkiye, in conjunction with the FEBS Young Scientists' Forum, held immediately before the FEBS Congress. Several of the FEBS Excellence awardees volunteered to mentor a group of the Young Scientists' Forum (YSF) participants.

FEBS Short-Term Fellowships
50 eligible Short-term Fellowships (STFs) applications were received for 2025 and 25 were awarded. These funds enable active young scientists to work for up to two or three months in laboratories in another FEBS

country.

FEBS Summer Fellowships
35 eligible Summer Fellowship applications were received and 10 were awarded to promising Masters/PhD students to provide a laboratory experience. This scheme closed at the end of 2025.

Ukrainian Short-Term Fellowships (USTs): these were introduced in spring 2022 to help scientists in or displaced from Ukraine. They support visits to a host laboratory for up to 4 months. The decision for acceptance is given rapidly - usually within 3 weeks of applying. 6 USTs were awarded in 2025, the value of the financial support ranged from 1 to 4 months.

FEBS Booster Fund
This scheme first opened in 2024 and closed at the end of 2025. The scheme provides grants for early PIs who have limited funds available to undertake research at present, who show great potential. 27 applications were received in 2024 with 8 awarded and, in 2025, 36 applications were received with 7 awarded.

PROBio-Africa Fellowships
This is a joint venture between FEBS, IUBMB and FASBMB (African Federation). The programme enables PhD students and postdoctoral fellows (who are affiliated with FASBMB) to spend at least three and up to six months in the laboratory of an established scientist in a FEBS member society country.

For 2025, 17 eligible applications were received and 7 applications were awarded.

PROBio-Latin America (LatAm) Fellowships
This is a joint venture between FEBS, IUBMB and PABMB (Pan-American Association). The programme enables PhD students and postdoctoral fellows (who are affiliated with PABMB) to spend at least three and up to six months in the laboratory of an established scientist in a FEBS member society country.
For 2025, 20 eligible applications were received and 8 applications were awarded.

Advanced Courses
In 2025 20 courses took place (4 Advanced Lecture Courses, 6 joint FEBS/EMBO Lecture Courses, 1 Practical Course, 1 combined Practical and Lecture Course, 2 Special Meetings and 6 Workshops) with continued IUBMB and EMBO support. 2025 celebrated more than 50 courses co-funded by FEBS and EMBO since 2005. FEBS Advanced Courses provide research updates and teaching from scientific leaders in a particular field and are particularly valuable for early-career researchers. Interaction of participants with experts and peers is facilitated through a variety of session formats.

In 2025, basic grants to course organisers totalled approximately €376,000. Furthermore, Youth Travel Fund (YTF) grants, which in 2025 totalled €65,000 were given to support participation in Advanced Courses to 122 young members of FEBS Constituent Societies from outside the host country (82 YTFs were given in 2024). In addition, 10 IUBMB-transcontinental YTFs supported the participation of students outside the FEBS area.

FEBS Press collaboration:
- *FEBS Letters*: poster prizes at 5 Advanced Courses, a meeting report and 8 planned articles;
- *FEBS Open Bio*: poster prizes awarded at 8 Advanced Courses; 3 planned Special Issues (from 3 courses) and 2 articles.
- *The FEBS Journal*: poster prizes at 2 Advanced Courses and 3 planned articles;
- Course organisers encouraged to contribute high-quality material in the form of a Special Issue or a Virtual Issue, this provides organisers with the opportunity to gain broad visibility of their work in well-reputed journal;
- a FEBS Press Editor attends each Advanced Course and gives a short presentation, with a focus on the journal the Editor works for. If invited to do so, the Editor will also give a talk related to publishing. Special content authored by Advanced Course invited speakers is often commissioned before or during the Course.

The 49th FEBS Congress

The annual FEBS Congress is overseen by the FEBS Congress Counsellor (who, in 2025, was Prof. Piotr Laidler), jointly with the Secretary General (who, in 2025, was Prof. Miguel A. De la Rosa). The 49th FEBS Congress, with the title *Mining biochemistry for human health and well-being*, took place from 5th to 9th July 2025 in Istanbul, Türkiye and was hosted by the Turkish Biochemical Society (TBS). The Congress bid was accepted in a vote by the FEBS Council at their meeting in 2020.

The Congress attracted 2,020 participants (including all registration categories, speakers and exhibitors) from 67 countries and the event featured an attractive scientific program comprising 13 plenary lectures, 82 session speakers across 17 symposia sessions and 6 special sessions covering educational, societal and scientific issues, workshops, the YSF Bridge and Science in the Street event for members of the public, as well as 33 short talks, 69 speed talks, poster sessions and 1,410 abstracts were accepted.

FEBS continued to provide specific additional funding support for Ukrainian scientists, or those displaced from Ukraine who submitted abstracts to the 2025 Congress (as was offered at the 2022, 2023 and 2024 Congresses).

In addition to providing a grant for the organisation of the Congress, FEBS continues to support the participation of young scientists at the event through Congress bursaries and through its Young Scientists' Forum awards (usually 100 participants, including the organising committee). FEBS provides support with reduced registration fees for FEBS members of Hinari (Research4Life) countries in the FEBS area called the Sprinzl Scheme.

Congress Management and Development and future Congresses

The future FEBS Congresses and Young Scientist Forums (YSF) will be as follows:

- the 50th FEBS Congress, hosted by the Netherlands Society for Biochemistry and Molecular Biology (NVBMB), will take place in Maastricht, Netherlands, 4th – 8th July 2026, preceded by the 25th FEBS YSF in Wageningen, Netherlands;
- the 51st FEBS Congress, hosted by the Latvian Biochemical Society, will take place in Riga, Latvia 3rd to 7th July 2027, preceded by the 26th FEBS YSF in Parnu, Estonia;
- the 52nd FEBS Congress, hosted by the Biochemical Society UK, will take place in Belfast, UK 1st to 5th July 2028, preceded by the 27th FEBS YSF also in Belfast.

FEBS continues to take out a cancellation insurance policy for each Congress and, although event insurance cover has changed because of the COVID-19 pandemic, FEBS takes out this insurance policy, as an example of FEBS' responsibilities as a charity to manage risk and effectively deliver its aims, along with the contracts in place with the Professional Congress Organiser (PCO) and Host Society.

Young Scientists' Forum

The Chairperson of the Careers of Young Scientists Committee, Prof. Irene Díaz-Moreno, and an organising committee of young scientists organised the YSF. The 24th YSF took place in Sapanca, Türkiye on 2nd to 5th July 2025. 353 applications were received from 30 countries. 100 pre-and post-doctoral young scientists from FEBS member societies, representing 30 FEBS member society countries, attended the event, supported by grants from FEBS and 2 places supported by the Biochemical Society (UK) and 2 places supported by IUBMB. The program consisted of an Opening Lecture and 4 Keynote Lectures, 7 'YSF Career Speakers' across 5 sessions on 'Career Skills', 10 selected short talks across 2 sessions, 2 sessions for '1minute poster presentations as well as social activities. YSF participants also attended the Congress, during which the YSF Bridge event was held. This event was organised by the Chairperson and an international organising committee of young scientists.

ENABLE

The FEBS-IUBMB-ENABLE conferences are 3-day international and interdisciplinary events for PhD students and postdocs, hosted at different research institutes each year. These events are organised by young scientists for other young scientists, and they offer an opportunity to learn, network, explore career options, and gain skills in outreach and science communication.

The FEBS-IUBMB-ENABLE Symposium was held in Glasgow, Scotland in 2025 (following events in Europe in 2022 and 2023 and in Singapore in 2024).

The 4th FEBS-IUBMB-ENABLE 2025 conference, with the title 'Bridging minds – interdisciplinary research for the future of life sciences', was hosted by the Cancer Research UK (CRUK) Scotland Institute in Glasgow on 10 – 12 September 2025. More than 180 young researchers participated from 25 countries, representing 48 nationalities within and outside of the EU. The 3-day conference included a scientific symposium, 16 career speakers, 8 keynote lectures and workshops on personal and professional development. 28 travel grants were funded by the consortium.

The agreement between FEBS, IUBMB and ENABLE partners (IRB Barcelona and SEMM Milan) was renewed for the period 2026 – 2029. The 5th ENABLE Conference in 2026 will be held in Krakow, Poland. The renewed agreement increases the budget for each event, and all conferences will be held in Europe. In addition, all travel grantees must be members of the FEBS Constituent Society. The collaboration with FEBS Press will continue with the publication of the conference report and abstracts in a FEBS Open Bio supplement.

FEBS 3+ Meetings and FEBS National Lectures
FEBS supports scientific events of its Constituent Societies through the FEBS3+ meetings program and the FEBS National Lecture scheme, overseen by the FEBS Congress Counsellor (Prof. Piotr Laidler in 2025).

The FEBS3+ meetings program provides funding for meetings organised through collaborations of at least three FEBS Constituent Societies. FEBS approved three applications for 3+ meetings in 2025: hosted by the Lithuanian Biochemical Society in Vilnius, Lithuania, in conjunction with the societies of Estonia and Latvia; hosted by Czech Society for Biochemistry and Molecular Biology in Prague, Czech Republic, in conjunction with the societies of Slovakia, Poland and Germany; and hosted by the Serbian Biochemical Society in Belgrade, Serbia in conjunction with the societies of Croatia, Hungary, Slovenia and Bosnia and Herzegovina. FEBS support consists of €10,000 to the host society for general meeting organisation and €10,000 to support the attendance of young scientists from the other participating societies.

In 2025, FEBS supported four FEBS National Lectures, by funding the attendance of key speakers from a different FEBS country invited by a FEBS Constituent Society to their national meeting through FEBS National Lecture Awards. The four FEBS National Lectures were awarded to national society meetings of the member societies of Norway, Hungary, Spain and Poland.

Other events
In the framework of promoting FEBS' journals and FEBS' collaborations with related international organisations of molecular life sciences, FEBS continues to support, through sponsorship of events and travel costs for distinguished speakers to deliver lectures at annual meetings of learned societies of biochemistry/molecular biology/cell biology in parts of the world with rapidly developing contributions to molecular life sciences research.

Science & Society (S&S)
The Science and Society Committee activities in the year 2025 included:
1. The Science and Society Special Session during the FEBS Congress in Istanbul, July 2025, held as a Science in the Street event, entitled 'Groove on the Brain: How Jazz shapes the Mind'. This event was a collaboration with the Istanbul Jazz Festival, bringing scientists and musicians together in a live performance exploring the relationship between music and the brain. The event was open to members of the local community, alongside participants of the Congress.
2. Participating in Biomedical Alliance activities. Through active participation in activities of Biomed Alliance (General Assemblies, Policy officers' meetings and task forces) the S&S Committee contributes to the shaping of European policy.
3. Joining in Initiative for Science in Europe (ISE) activities. FEBS became a full member in 2024.
4. Participating in the FEBS Network.

Education
The Education Committee has the mission of promoting education and training of the highest quality in molecular life sciences in Europe at both undergraduate and postgraduate levels. The committee's activities include: organising and funding education events, running the Education Ambassadors initiative, supporting the open access journal FEBS Open Bio's section devoted to education and overseeing and contributing to the Educator Channel on the FEBS Network. FEBS Education Committee also works collaboratively with FEBS Advanced Courses Committee and FEBS Careers of Young Scientists Committee.

Activities held in 2025:

Education Committee Meetings: the committee met in-person in May 2025 in Tallinn, Estonia and in Bergen, Norway in September 2025 in conjunction with the joint workshop (see below).

FEBS supported Society Education Events
ABMBBH (Association of Biochemists and Molecular Biologists in Bosnia and Herzegovina) organized the symposium 'The Next Generation Biotechnologists' in May 2025. The call in 2025 led to applications being approved for educational events organised by the following societies:
Croatia: 'Better Skills for Better Jobs: A Smart Lab Book for Productive Research' workshop (November 2025);
Portugal: 'Pedagogical Innovations in Biosciences: Sharing Practices, Embracing Innovation' online workshop (October 2025);
Morocco: 'From threats to opportunities: Rethinking education in the age of emerging technologies (AI, Open Science, Digital Transformation)' in collaboration with the ENS Casablanca, as a workshop (November 2025);
Cyprus: 'Developing Critical Thinking in Molecular Life Sciences in the AI era: challenges and solutions' event (February 2026).

FEBS Joint Education events
Education Workshop: FEBS and the Norwegian Bioscience Society held a joint Education and Training Workshop: 'Teaching Large, Thinking Deep: Active Learning and Assessment in Expanding Classrooms' at the University of Bergen, Norway in September 2025, including a module from the Education and Training Academy on Active Learning.
IUE and FEBS joint training event: 'Discipline-based Education Research' (held in Izmir, Türkiye in Feb. 2026).

FEBS Education Award
Following the launch of this award in 2024, in FEBS 60th anniversary year, and an open call for nominations, the 2025 recipient of the FEBS Education Award is Prof. Yoav Arava (Israel Society for Biochemistry and Molecular Biology). Prof. Arava received the Award in conjunction with the 49th FEBS Congress.

FEBS Education National Lecture
Following the launch of the FEBS Education National Lecture Award in 2024, the second call concluded with the selection of the Belgian society's application for the Education National Lecture to be delivered by Prof. Ezgi Karaca (Türkiye) at their 2025 National Meeting.

FEBS Virtual Ambassador Meeting: an online meeting was held in April 2025 with 27 FEBS Education Ambassadors participating.

Education White Paper
The Education and Training Committee wrote a white paper following on from the Education and Training Conference, entitled 'Challenges, opportunities and action plans for transforming molecular life sciences education', published in *FEBS Open Bio*.

International Collaborations and Outreach
- FEBS agreement with IUBMB includes a joint symposium which was held at the IUBMB Education Symposium in Malaysia, August 2025.

- FEBS held a joint session with Orpheus on PhD Education as part of the FEBS Congress in Istanbul, 2025.
- The Committee Chair attended the FAOBMB Conference in South Korea in May 2025 to chair the Education Plenary Lecture.

49th FEBS Congress Education Activities 2025
FEBS Education Committee organised several activities at the 49th FEBS Congress:
1. Education Plenary Lecture delivered by Prof. Robert Harris, as the 2024 Education Award recipient.
2. Joint Education Session with IUBMB 'From challenges to opportunities: Integrating AI in biosciences education'.
3. FEBS-Orpheus joint session focused on PhD education: 'PhD training in a changing world: Standards, ethics and career growth'.
4. Education posters: more than 35 posters presented on undergraduate and postgraduate teaching.

Integration and Networking Committee (INC)

The Committee was chaired in 2025 by Prof. Jerka Dumić. The INC's primary goal is to promote and facilitatecommunication and collaboration among Constituent Societies, supporting and advising them in strengtheningand developing their activities and in fostering cohesion and connectivity within FEBS. Additionally, it activelycontributes to the coordination and harmonisation of FEBS initiatives and programmes and promotes networking and communication of FEBS with other organisations and institutions in Europe and worldwide. Thus contributing to FEBS' global visibility and recognition in the field of molecular life sciences. The INC oversees and activelycontributes to the development and functioning of the FEBS Network.

Activities of the Integration and Networking Committee during 2025 included:

- **Member Society Representatives (MSRs) programme** (one representative from each member society not including Belarus and Russia who are suspended from FEBS activities): 4 meetings during the year, 3 online and the main meeting in-person during the Congress. At the in-person events at the FEBS Congress 2025, meetings included a networking session, meeting with FEBS EC members and with FEBS Press to learn more at first hand of FEBS activities and FEBS Press journals. Data compiled by FEBS on their society's participation across FEBS different events and initiatives is shared with MSRs with the purpose of enhancing their society's engagement with FEBS, to network with each other and to contribute to a dedicated MSRs session in the Congress program. Other MSRs activities during the year included a dedicated 'room' on the FEBS Network platform to share good practice and ideas. FEBS provided support to each MSR to attend the Congress and MSRs meetings and 29 of the 37 MSRs attended in Istanbul.

- **Scientific Advisory Committee** (chaired by the INC Chairperson) with nominations from MSRs on behalf of each FEBS member society (excluding Belarus and Russia) to propose names for the scientific program of the FEBS Congress. For the 2025 Congress, 26 nominations as speakers were accepted. For the 2026 Congress, 24 nominations were accepted.

- **IUBMB-FEBS-FASBMB PROBio-Africa Fellowships**: the INC Chairperson coordinated this fellowship Scheme in 2025, in conjunction with the Fellowships Committee Chair, whereby FEBS contributes €25,000 and IUBMB contributes €25,000 to the fund for fellowships open to eligible applicants with a PhD and postdoctoral fellows in African countries affiliated with FASBMB to work in a laboratory in a FEBS member society country for up to six months with an award of €7,000 comprising €2,000 for travel costs and €5,000 for living costs during the fellowship. There were 19 applications, 18 eligible, resulting in 7 awardees.

- **IUBMB-FEBS-PABMB PROBio-LatAm Fellowships**: this is a new collaboration between FEBS, IUBMB and the PABMB; the INC Chairperson coordinated this fellowship scheme in 2025, in conjunction with the Fellowships Committee Chair. Up to 7 fellowships, ranging from 1 – 6 months to a maximum value of €7,000 were awarded in 2025. There were 22 applications, 18 eligible, resulting in 8 awardees.

- **Israel Pecht Award 2025**: following the inaugural award in 2024, FEBS 60th anniversary, the call for nominations for the 2025 award was held and the 2025 award recipient was chosen by the panel as Zrinka Kovarik nominated by the Croatia society. The award recognises individuals for their outstanding contributions to their respective FEBS constituent society and to FEBS.

- **INC visits / meeting attendance in 2025**: at the Education Ambassador Workshop in Tunisia; FAOBMB Congress in Korea; ENABLE Conference committee member and attending Education Committee meetings.

- **Sprinzl Scheme**: the INC provided financial support under the 'Sprinzl Scheme' with a 50% registration fee discount for scientists resident (studying/working) in Armenia, Bosnia and Herzegovina, Georgia, Moldova, Morocco, Tunisia and Ukraine to attend the 2025 FEBS Congress in Istanbul.

The FEBS Network
The FEBS Network is an international online forum for scientists working in the molecular and cellular life sciences. It is used to share information, news and insights, as well as to connect and collaborate – with the ultimate goal of helping to advance progress in these research areas.

The FEBS Network currently presents most content from its invited experts and contributors in four themed 'channels': Research, Early-Career Scientist, Viewpoints and Educator. In addition, there are 'rooms' which host content for specific FEBS community groups, for delegates attending certain FEBS events, or for scientists interested in particular subtopics. FEBS Constituent Societies are also able to post news in a FEBS Societies channel.

The FEBS Network has developed from a collaboration between FEBS and its journal publisher Wiley which provides financial support for the maintenance and licensing costs of the Network, and is hosted using software which specialises in creating expert-led networks.

Most information is presented in the form of posts, authored by scientists, policy-makers, educators and other professionals in the molecular life sciences. Contributors span a wide career spectrum, from directors of key research institutes in Europe, highlighted by the Director Visions series, to the activities from the students and young researchers of the FEBS Junior Section.

Women in Science
The activities of the Working Group on Women in Science (WISE) with Prof. Dame Caroline Dean as Chairperson in 2025, were:

1. Selection of the FEBS/EMBO WiS 2026 winner: The award highlights the major contributions made by female scientists to life sciences research. Winners of the award will serve as inspiring role models for future generations of women in science. In conjunction with the 2025 award winner's plenary lecture at the FEBS Congress in Istanbul, the award panel also met during the Congress following the call for nominations for the 2026 winner. The 2025 winner was Asifa Akhtar from MPI Freiburg.

2. Women in Science lunch at the FEBS Congress: a social and networking event with an emphasis on supporting interactions between early-career female researchers with each other and senior scientists for the discussion of equality and career-related issues.

OBJECTIVES AND ACTIVITIES FOR THE PUBLIC BENEFIT

The overall objective of FEBS is to contribute to and promote the advancement of research and education for the public benefit in the sciences of biochemistry, molecular biology and related disciplines. As indicated by the specific key objectives of FEBS set out above under 'Objectives', FEBS does this particularly through:

- funding forums for presentation and discussion of research results and related areas of interest at its large annual Congress, Young Scientists' Forum (YSF), FEBS Excellence Awards Meeting, Special Meetings and other Advanced Courses; promoting training through lectures courses, workshops and practical courses of its Advanced Courses programme, as well as its education workshops; and supporting participation of promising young scientists in these events through YSF awards, Youth Travel Fund grants and Congress bursaries;
- facilitating and supporting the exchange of scientific information between biochemists and molecular biologists especially in Europe and other countries of FEBS Constituent Societies principally through these forums and mechanisms, but also through Constituent Society meetings (National Lecture scheme), FEBS3+ meetings, FEBS Excellence Awards and Short-Term Fellowships (which promote mobility), and schemes to support integration of bioscientists working in economically disadvantaged countries of the FEBS area;
- providing stipends through its FEBS Excellence Award programme to allow research to be carried out in host laboratories by talented early-career scientists;
- offering high-quality publication of research findings for both authors and readers through its four international molecular life science journals.

Through the many activities of FEBS outlined above, the beneficiaries of FEBS include scientists at all levels directly engaged in research and education in the molecular life sciences, and ultimately humankind across the globe through the contributions of these areas of science to human health, agriculture, biotechnology and related areas, and enrichment of human knowledge.

FEBS wholly owns its international journals, which are of importance to FEBS both by directly contributing to its objectives and as a source of income to support its other purposes. FEBS follows all directives on Open Access publishing from the UK, EU and relevant research funders across the world. Two of the FEBS publications – FEBS Open Bio and Molecular Oncology – are fully open access. Its two hybrid journals – The FEBS Journal and FEBS Letters – offer authors open access options, often with no direct cost to authors at institutions with a transformational agreement. In addition, authors are able to deposit accepted research articles, as required by funders, in institutional repositories, through which they are accessible to the public, and all published articles in our hybrid journals are freely available after 12 months to all readers.

FEBS events are normally open to scientists throughout the world. Recipients of FEBS grants for fellowships and for support of participation in meetings are normally required to be members of FEBS' Constituent Societies (where membership criteria are those expected of learned societies) and resident within the FEBS area of Europe and neighbouring countries. Some FEBS programs particularly benefit disadvantaged scientists.

The trustees confirm that they have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the organisation's aims and objectives and in planning future activities.

Grant Making Policy
The overall objective of FEBS is to contribute to and promote the advancement of research and education for the public benefit in the molecular life sciences and related disciplines. Policies for key grants awarded by FEBS to achieve these goals are outlined below.

FEBS Excellence Awards and Short-Term Fellowships
As part of our commitment to young scientists under the FEBS Fellowship program set up in 1978, and to further research in the molecular life sciences, we offer Short-Term Fellowships to members of Constituent Societies, as well as Summer Fellowships to promising Masters/PhD students. The FEBS Excellence Award program launched in 2021 is intended for early-career scientists who have been PIs in their Host Institution for at least one year and are in a salaried capacity. Ukrainian Short-Term Fellowships are specifically for active molecular life scientists who are resident in Ukraine at the point of application, or displaced from Ukraine as a result of war

in the country. These Fellowships are for short-term visits to a host laboratory for a period of up to 4 months and are for use for travel to the host laboratory and living subsistence for the duration of the Fellowship. Our Fellowships are intended to allow members of our Constituent Societies working in a FEBS country to work in a laboratory in another FEBS country.

Eligibility criteria for FEBS Excellence Awards and Fellowships are set out in detailed guidelines on the FEBS website. The initial applications are assessed on merit by the FEBS Excellence and Fellowships Committee. Within three months of completion of all Fellowships, awardees are required to prepare a final report on the work carried out during the tenure of the Fellowship. Similarly, Excellence Awardees are asked to provide both a scientific and a financial report to be eligible for the 2nd and 3rd instalments.

Grants for organising FEBS Advanced Courses
Grants for organising FEBS Advanced Courses (including lecture courses, workshops, practical courses and special meetings) are awarded to senior scientists by the FEBS Advanced Courses Committee on a competitive basis. Reports (including scientific and financial) from the organisers are required within 3 months after the event.

Grants for young scientists attending Advanced Courses
Students participating in FEBS Advanced Courses (including lecture courses, workshops and practical courses) may apply for financial support through the FEBS Youth Travel Fund (YTF). In 2025, grants were made to persons travelling from their current country of residence to another country, mostly in the European area. Applicants for these grants should normally be registered as a student at an institution of higher learning in a country where there is a FEBS Constituent Society or be within five years of having completed a PhD thesis, be a member of a FEBS Constituent Society, and not have received a grant from the Youth Travel Fund to attend an Advanced Course in the current or preceding year or received a grant to attend the Young Scientists' Forum in the current year. Candidates are shortlisted by the Course organisers on merit.

Grants for organising the FEBS Congress, FEBS3+ meetings, and requests for National Lecture Support
FEBS evaluates bids for organising its yearly Congresses and also FEBS3+ meetings, as well as requests from Constituent Societies for National Lecture support, according to their quality; the administrative responsibility for these is in the hands of the FEBS Congress Counsellor (Prof. Piotr Laidler in 2025).

Grants for attending the FEBS Young Scientists' Forum and Congress (YSF awards*)*
Recipients of YSF awards are selected by the Careers of Young Scientists Committee Chair (Irene Díaz-Moreno in 2025) and the local organising committee on merit, with eligibility criteria normally including: i) be a PhD student or postdoctoral fellow within 5 years of finishing his/her PhD at an institution of higher education in a country where there is a FEBS constituent Society; ii) be under 35 years old; iii) be a member of a FEBS Constituent Society; having not attended a recent YSF and not received a Youth Travel Fund award the same year.

Congress bursaries
Recipients of bursaries (which offer financial support with registration, travel and accommodation costs for the Congress) are selected by the host society of that year's Congress on merit, with eligibility criteria similar to those for YTF and YSF awards.

Achievement and performance
This section summarises and assesses our principal achievements in 2025 against the formal objectives of FEBS. More details of the activities included in brief here can be found in the ‘Activities’ section above.

Objective 1: holding and arranging congresses, training and educational courses on matters connected with biochemistry and molecular biology and related disciplines

Achievements	Comments
2025 20 courses took place (4 Advanced Lecture Courses, 6 joint FEBS/EMBO Lecture Courses, 1 Practical Course, 1 combined Practical and Lecture Course, 2 Special Meetings and 6 Workshops.) The assessment procedure for course selection and funding refined, online database for applications and reporting enhanced, FEBS-owned and branded course websites introduced and collaborations with EMBO and IUBMB continued.	In 2025, FEBS continued to fund several Advanced Courses with high scientific content and also funded YTF grants to allow participation of young researchers at the FEBS courses.
FEBS3+ Meeting(s): FEBS supported 3 FEBS3+ meetings in 2025: hosted by the Lithuanian Biochemical Society in Vilnius, Lithuania, in conjunction with the societies of Estonia and Latvia; hosted by Czech Society for Biochemistry and Molecular Biology in Prague, Czech Republic, in conjunction with the societies of Slovakia, Poland and Germany; and hosted by the Serbian Biochemical Society in Belgrade, Serbia in conjunction with the societies of Croatia, Hungary, Slovenia and Bosnia and Herzegovina. Each FEBS 3+ meeting receives support comprising €10,000 to the host society for general meeting organisation and €10,000 to support the attendance of young scientists from the other participating societies.	Support for scientists in 12 societies creating enhanced links between these FEBS Constituent Societies. See 'Support for Constituent Society events' section for more details.
24th Young Scientists Forum (YSF) and 49th FEBS Congress: The 24th YSF took place in Sapanca, Türkiye in July 2025. The 49th Congress was held in Istanbul, Türkiye in July 2025.	The YSF includes over 100 PhD students and young postdocs, whose attendance at this and the Congress is funded by FEBS YSF awards. In addition, FEBS supports participation of a significant number of young scientists in its annual Congress through the FEBS Bursaries scheme. The annual FEBS Congress provides a platform for international scientific exchange and showcases the newest developments in biochemistry, molecular biology and related areas. The Congress comprises plenary lectures, symposia, poster sessions, workshops and other activities on related topics. The Congress is held in countries with a Constituent Society of FEBS.

Objective 2: facilitating and supporting the exchange of scientific information between biochemists, molecular biologists and scientists working in related disciplines generally and especially in Europe and other countries of Constituent Societies

Achievements	Comments
FEBS Congress, Advanced Courses and Education Workshops See above	See above
Lecturers for Constituent Society and other scientific meetings National Lectures awarded to national meetings of the member societies from Norway, Hungary, Spain and Poland.	Effective enhancement of regional, national and international meetings by funding of distinguished speakers.
Other meeting support and collaborations FEBS Lecture at the 31st FAOBMB Conference (FAOBMB2025) in Busan, Korea 20-23 May 2025.	Eminent speakers for special events and meetings beyond Europe, which also allowed collaboration with international organisations and yielded FEBS journals' promotion.

Achievements	Comments
FEBS Excellence Awards and Fellowships Fellows move to work in host lab in different country (see Objective 3 below).	Promotion of exchange of skills/knowledge.
Integration schemes Support for communities of molecular life scientists in European countries with economic challenges and/or no existing or active biochemical society through visits, the Congress 'Sprinzl Scheme', and Education Workshops as well as encouraging the establishment of new societies and for them to benefit from FEBS.	Contributes to developing/maintaining pool of effective researchers in Europe.

Objective 3: facilitating and supporting the training of young scientists in research, in the form of fellowships

Achievements	Comments
Short-Term Fellowships 25 Short-Term, 10 Summer Fellowships and 6 Ukrainian Fellowships.	Enhances research possibilities for young scientists; numbers awarded in accordance with budgetary limits.
Excellence Awardees 10 new Excellence Awardees in 2025, following annual call since 2021.	Very competitive - only the most outstanding scientists successful; they must be recognised scientists in their field and should possess an outstanding track record. Accounts for major part of FEBS expenditure.
FEBS Excellence Awardees Meeting In 2025, the second meeting was held in Sapanca, Turkiye, in conjunction with the YSF, immediately before the FEBS Congress.	EA recipients are invited to participate. No selection procedure applies as only current and/or recently completed FEBS Excellence Awardees are eligible.

Objective 4: organising the editing and publication of scientific research and educational material in biochemistry and molecular biology and related disciplines

Achievements	Comments
Our journals continue to maintain high standards of peer review. 71% of all articles published were open access.	Strong performance of FEBS' Press journals in a challenging scientific publishing environment.

The current Publishing Agreement between FEBS and Wiley runs from 2024-2028. The four-year contract is based on revenue share, guaranteed income and special support for the FEBS Network.

Financial review

Journal income and costs
Total income from royalties in 2025 was €5.8M 5.4% higher than the royalty income in 2024 (€5.51M) due an increase in published papers. The total costs for the four FEBS journals, FEBS Journal, FEBS were €1.98M 7% higher than 2024 (€1.85M). This is due to higher support costs for the journals. These costs include the direct costs of employees working on the journals and editors' payments.

Distribution of expenditure on FEBS activities
In 2025, Fellowships remained by far the highest area of charitable FEBS spending at €1.3 M (€1.1 M in 2024) then Advanced Courses, course grants and YTFs totaling ~€441,000; (~€409,000 in 2024).

FEBS bursaries awarded for participation in the FEBS Congress totaled €143,000 (€144,000 in 2024), and the YSF (Young Scientist's Forum) provided spaces for 100 participants to a scientific meeting and the Congress €165,000 (€152,000 in 2024).

The support given to the Congress directly was €271,000 (€205,000 in 2024), excluding bursaries and the YSF. FEBS also jointly supports the ENABLE event with funding of €53,000 (€69,000 in 2024) alongside the IUBMB. Other Special Initiatives include fellowships for Ukrainian Scientists €69,000 (€33,000 in 2024).

Prizes and awards in life sciences including the Women in Science Award (€10,000) which is shared with EMBO, and publication prizes totaled ~€42,000 (~€52,000 in 2024). Funding of lecturers for meetings within and outside of Europe including three FEBS 3+ meetings and other areas of FEBS work - including education workshops, science and society sessions, and 'integration' initiatives were ~€229,000 (€168,000 in 2024) in total.

Governance and support costs
The senior scientists who serve as FEBS Officers and members of FEBS committees all work pro bono, and the holders of key positions in the FEBS Executive Committee generously devote considerable time and energy to FEBS activities. There are a small number of support personnel working in the FEBS Central Office dealing with central administration, events, and the FEBS Treasury Office which deals with all financial matters. Outside the Central Office there are personnel working for the Fellowships Committee, Advanced Courses Committee and the Career of Young Scientists Committee to support the activities of the committees and committee chairs. In addition, FEBS has personnel working on strategic marketing and communications.

The total governance costs, including the expenses associated with higher-level committees (Council, Executive and Finance) within FEBS, Central Administration Office, The Treasury office and Secretary General expenses, Strategic Marketing as well as auditor and other professional service fees, amounted to about €1.1M (24%) of the charitable spending €4.78M in 2025. In 2024 governance costs were €1.0M (25%) of €4.7M. These governance costs are not included in the total for charitable spending.

An indication of the support costs involved in running the two activities of FEBS with the highest expenditure can be given by the committee expenses as a percentage of the charitable spending in that area; in 2025, this was approximately 5% of the total Fellowships grants, and 10% for Advanced Courses grants (in 2024, this was 6%

of the total Fellowships grants, and 17% for Advanced Courses grants). Support costs for the journals are covered in 'Journal income and costs' above.

Investment performance
For the twelve months to the 31 December 2025 the combined investment portfolios held by FEBS' investment managers achieved a return of +3.6% (+13.1% in 2024).

Most of FEBS' holding are held in portfolios with JPM (€59.2M Dec 2025). The holdings include a managed portfolio, private equity, and short-term deposits.

In addition, at 31 Dec 2025, multi-asset portfolios were held with Cazenove (€36.0M), Sarasin (€3.2M) and CCLA (€5.4M). FEBS, also, holds two property portfolios, one with CCLA (€2.8M) and the other with PITCH / Swiss Life (€2.7M) and an additional cash deposit with CCLA (€2.5M).

Principal risks and uncertainties
The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.

Continuing Reduction of income due to changes in journal publishing
In addition to directly fulfilling one of the charitable objectives of FEBS, our journals have provided the main source of income to fund FEBS' other charitable work. FEBS has already experienced a significant reduction in this income in recent years. There is a risk that income from this source is likely to be reduced further in the future as publishing moves to new open-access models, driven by funder mandates for open access publication.

FEBS is addressing these concerns by (1) its policy on reserves (see below) so that future income can be derived from investments and (2) its negotiated long-term contract with a commercial publisher which, in turn, is negotiating deals with library and funding consortia that combine open access publication rights with traditional 'reading' access to the FEBS Press journals. The FEBS Publications Committee has developed a strategic plan to ensure that its journals adapt to evolving publishing requirements.

Investment Management
All decisions about investments are made by the Finance Committee, as delegated by the Executive Committee. On occasion the Finance Committee may seek further approval from the Executive Committee on significant investment commitments.

Internal Controls
FEBS' systems and processes are monitored regularly. The Finance Committee is responsible for maintaining proper accounting records which disclose with reasonable accuracy at any time the financial position and to enable them to ensure that the financial statements comply with all statutes and regulations. FEBS' controls include regular internal and external oversight and checks. Controls and procedures are appropriate for the organisation's size and operation. FEBS uses accounting software from a large, reputable supplier and The Treasury department has several processes to ensure the appropriate use of funds, the management of the accounts and recording of all transactions. Duties within the Treasury are separated, and robust systems of oversight and authorisation are in place. The cash-flow is regularly monitored to ensure all liabilities are met in a timely manner.

Impact on overall objectives
The success of FEBS in promoting the advancement of research and education for the public benefit in the sciences of biochemistry, molecular biology and related disciplines is carefully monitored by stringent peer review and other methods.

Plans for future periods

Reserves policy

The total value of funds held by FEBS at 31 December 2025 was €116.1M (€112.7M in 2024) including cash at FEBS' bank. None of the funds were restricted funds or unavailable for the general purposes of the charity at the end of the reporting period and no material amounts have been designated or are otherwise committed as at the end of the reporting period.

As at year end 2025, approximately 85% of funds including investments could be realised in fewer than 3 days, 10% were in investments that may be realised in up to 10 years and the rest had varying timescales of up to 6 months, in which the assets may be realised.

The investments in private equity and infrastructure are illiquid over a short timescale. These investments will be held by JPM for up to 10 years and up to 8% of the total investment portfolios will be held in private equity and 5% in infrastructure.

The Treasurer of FEBS' regularly reviews the performance of FEBS investments during the year. Significant changes in investments and the treatment of funds are discussed and approved by the FEBS Finance Committee and where appropriate, are submitted for further approval from the FEBS Executive Committee.

The FEBS' reserves policy allocates €6M for one year's essential funding and this is held in cash in an interest bearing account at the bank.

The FEBS Trustees have approved the enhancement of the investment portfolio to reach a value that may generate funds to offset potential changes in income due to the new publishing model. The income from the portfolio in addition to royalty income will ensure that FEBS exists in perpetuity providing funding for the running of the journals and its other charitable activities.

Future commitments and plans for other areas of FEBS work


We now have firm arrangements for a programme of Annual Congresses until 2030, as these involve substantial forward planning. Expenditure on Advanced Courses up to 2027 and the costs of annual extensions of FEBS Excellence Awards to up to 3 years for awardees already in post, are included in our budgets.

With regard to future activities, we are also continuing to forge closer links with related European and worldwide organisations that cover contiguous/overlapping areas of molecular life sciences (e.g. biophysics, microbiology, immunology, cancer) with the aim of maximising the use of our impacts and resources.

Concluding Comments

FEBS has continued to operate successfully in promoting the advancement of research and education for the public benefit in the sciences of biochemistry, molecular biology and related disciplines, and its current strategy for its long-term survival is progressing smoothly and according to plan. By making provisions with its reserves FEBS will be in a position to provide support to many researchers in years to come.

Approved by order of the members of the board of Trustees and signed on their behalf by:



Professor M De La Rosa
Trustee

Date: 10 September 2026

STATEMENT OF THE TRUSTEES' RESPONSIBILITIES FOR THE YEAR ENDED 31 DECEMBER 2025

The Trustees (who are also the directors of the Company for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial . Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees and signed on its behalf by:



Professor M De La Rosa
Trustee

Date: 10 September 2026

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES

OPINION

We have audited the financial statements of The Federation of European Biochemical Societies (the 'charitable company') for the year ended 31 December 2025 which comprise the Statement of Financial Activities, the Balance Sheet, the Statement of Cash Flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2025 and of its incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

CONCLUSIONS RELATING TO GOING CONCERN

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

OTHER INFORMATION

The other information comprises the information included in the Annual Report other than the financial statements and our Auditors' Report thereon. The Trustees are responsible for the other information contained within the Annual Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

OPINION ON OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' Report for the financial year for which the financial statements are prepared is consistent with the financial statements.
- the Trustees' Report has been prepared in accordance with applicable legal requirements.

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Report.

We have nothing to report in respect of the following matters in relation to which Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the Trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the Trustees' Report and from the requirement to prepare a Strategic Report.

RESPONSIBILITIES OF TRUSTEES

As explained more fully in the Trustees' Responsibilities Statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

AUDITORS' RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- We obtained an understanding of the legal and regulatory frameworks through our accumulated knowledge and consideration of sector information that is applicable to the charitable company. We determined that the most significant which are directly relevant to specific assertions in the financial statements are those related to the financial reporting framework including but not limited to United Kingdom Generally Accepted Accounting Practice, the Charities Act 2011, Charities SORP, the Companies Act 2006, Data Protection Act 2018 and tax legislation

- We obtained an understanding of the procedures and controls over the charitable company's operations and discussed these with those charged with governance. No matters of fraud were brought to our attention during that discussion.

- During our discussions with management, they assessed these as being the normal risks required to be considered by us as auditors by the Auditing Standards (such as management override and revenue recognition) but confirmed that no irregularities here occurred. This was confirmed by our review of management meetings, auditing management override through journal testing, and other adjustments to consider appropriateness, review of the financial statements to ensure no unusual and / or inexplicable variances and general discussions with management during the course of the audit. We did not identify any significant business transactions outside the normal course of the business operations.

- Our senior statutory auditor has assessed that the audit team possessed the ability and competence to identify and recognise non-compliance with the relevant laws and regulations central to the operation of this charitable company. We have not identified any additional laws and regulations which are central to the entity's operations and which we were not notified about, during the course of our audit fieldwork.

We believe that our audit was capable of detecting material irregularities, including fraud, and our audit procedures were designed to respond to risks of material misstatement in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery, misrepresentations or through collusion. There are inherent limitations in the audit procedures performed and the further removed noncompliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we are to become aware of it.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities . This description forms part of our Auditors' Report.

USE OF OUR REPORT

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditors' Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinions we have formed.



Mark Murray BCom FCA FCCA (Senior Statutory Auditor)
for and on behalf of

Hill Wooldridge & Co. Limited

Registered Auditors
Monument House
215 Marsh Road
Pinner
HA5 5NE

Date: 10 September 2026

THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES

(A Company Limited by Guarantee)

STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31 DECEMBER 2025

	Note	Unrestricted funds 2025 €	Total funds 2025 €	Total funds 2024 €
INCOME FROM:				
Donations	3	**5,889**	**5,889**	5,745
Charitable activities	4	**5,802,586**	**5,802,586**	5,507,000
Investments	5	**2,036,428**	**2,036,428**	1,917,920
Other income	6	**64,680**	**64,680**	32,868
TOTAL INCOME		**7,909,583**	**7,909,583**	7,463,533
EXPENDITURE ON:				
Raising funds	7	**499,161**	**499,161**	424,572
Charitable activities	8	**5,414,783**	**5,414,783**	4,763,852
TOTAL EXPENDITURE		**5,913,944**	**5,913,944**	5,188,424
NET INCOME BEFORE NET GAINS ON INVESTMENTS		**1,995,639**	**1,995,639**	2,275,109
Net gains on investments	13	**1,365,950**	**1,365,950**	11,295,968
NET MOVEMENT IN FUNDS		**3,361,589**	**3,361,589**	13,571,077
RECONCILIATION OF FUNDS:				
Total funds brought forward		**112,728,488**	**112,728,488**	99,157,411
Net movement in funds		**3,361,589**	**3,361,589**	13,571,077
TOTAL FUNDS CARRIED FORWARD		**116,090,077**	**116,090,077**	112,728,488

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 22 to 41 form part of these financial statements.

THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES

(A Company Limited by Guarantee)
REGISTERED NUMBER: 08239097

BALANCE SHEET
AS AT 31 DECEMBER 2025

	Note		2025 €		2024 €
FIXED ASSETS					
Tangible assets	12		**28,938**		36,978
Investments	13		**109,121,483**		106,253,721
			109,150,421		106,290,699
CURRENT ASSETS					
Debtors	14	**1,783,898**		1,647,968	
Cash at bank and in hand		**5,610,985**		5,434,523	
		7,394,883		7,082,491	
CURRENT LIABILITIES					
Creditors: amounts falling due within one year	15	**(455,227)**		(644,702)	
NET CURRENT ASSETS			**6,939,656**		6,437,789
TOTAL NET ASSETS			**116,090,077**		112,728,488
CHARITY FUNDS					
Unrestricted funds	16		**116,090,077**		112,728,488
TOTAL FUNDS			**116,090,077**		112,728,488

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:



Professor F Michelangeli
Trustee

Date: 10 September 2026

The notes on pages 22 to 41 form part of these financial statements.

STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2025

	Note	2025 €	2024 €
CASH FLOWS FROM OPERATING ACTIVITIES			
Net cash used in operating activities	18	**(358,154)**	(930,713)
CASH FLOWS FROM INVESTING ACTIVITIES			
Dividends, interests and rents from investments		**2,036,428**	1,917,920
Proceeds from the sale of intangible assets		**-**	(28,089)
Proceeds from the sale of tangible fixed assets		**42,810,170**	35,368,999
Purchase of investments		**(44,311,982)**	(40,760,279)
NET CASH PROVIDED BY/(USED IN) INVESTING ACTIVITIES		**534,616**	**(3,501,449)**
CHANGE IN CASH AND CASH EQUIVALENTS IN THE YEAR		**176,462**	**(4,432,162)**
Cash and cash equivalents at the beginning of the year		**5,434,523**	9,866,685
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	19	**5,610,985**	5,434,523

The notes on pages 22 to 41 form part of these financial statements

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

1. ACCOUNTING POLICIES

1.1 BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011 and the Companies Act 2006. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The Federation of European Biochemical Societies meets the definition of a public benefit entity as defined by FRS 102.

There were no significant estimates or judgements made by management in preparing these financial statements.

The functional and presentational currency is the Euro.

1.2 GOING CONCERN

The Trustees have considered the Company's forecasts and projections. After making enquires, the Trustees have concluded that there is a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Therefore, these accounts have been prepared on the going concern basis.

There are no material uncertainties in relation to going concern.

1.3 INCOME

All income is recognised once the Company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Income from royalties is recognised in line with the period to which it relates.

Income from grants and donations are recognised when the Company has been notified in writing of both the amount and settlement date. In the event that a grant or donation is subject to conditions that require a level of performance before the Company is entitled to the funds, the income is deferred and not recognised until those conditions are fully met, or the fulfillment of those conditions is wholly within the control of the Company and it is probable that those conditions will be fulfilled in the reporting period.

Investment income is recognised in the period in which the Company becomes entitled to the income.

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Company; this is normally upon notification of the interest paid or payable by the Bank.

Other income is recognised in the period in which it is receivable and to the extent the goods have been provided or on completion of the service.

1. ACCOUNTING POLICIES (CONTINUED)

1.4 EXPENDITURE

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.

Expenditure on raising funds includes all expenditure incurred by the Company to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading. This comprises investment management fees.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Company's objectives, as well as any associated support costs.

Allocation of costs is based on activity which has driven the relevant cost.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

Governance costs are those incurred in connection with administration of the Company and compliance with constitutional and statuatory requirements.

1.5 FOREIGN CURRENCIES

Monetary assets and liabilities denominated in foreign currencies are translated into euros at rates of exchange ruling at the reporting date.

Transactions in foreign currencies are translated into euros at the rate ruling on the date of the transaction.

Exchange gains and losses are recognised in the Statement of Financial Activities.

1.6 TAXATION

The Company is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the Company is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

1.7 TANGIBLE FIXED ASSETS AND DEPRECIATION

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

1. ACCOUNTING POLICIES (CONTINUED)

1.7 TANGIBLE FIXED ASSETS AND DEPRECIATION (CONTINUED)

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives.

Depreciation is provided on the following bases:

Leasehold improvements	- over the life of the lease
Fixtures and fittings	- 15% on reducing balance
Computer equipment and website	- 25% on reducing balance

1.8 INVESTMENTS

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance Sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Statement of Financial Activities.

1.9 DEBTORS

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.10 CASH AT BANK AND IN HAND

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.11 LIABILITIES AND PROVISIONS

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of Financial Activities as a finance cost.

1.12 FINANCIAL INSTRUMENTS

The Company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1. ACCOUNTING POLICIES (CONTINUED)

1.13 OPERATING LEASES

Rentals paid under operating leases are charged to the Statement of Financial Activities on a straight-line basis over the lease term.

1.14 PENSIONS

The Company operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Company to the fund in respect of the year.

1.15 FUND ACCOUNTING

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Company and which have not been designated for other purposes.

2. CRITICAL ACCOUNTING ESTIMATES AND ARES OF JUDGEMENT

Estimates and judgements are continually evaluated and are based on historical experience and other factors. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. There are no estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year.

3. INCOME FROM DONATIONS

	Unrestricted funds 2025 €	**Total funds 2025 €**
Subscriptions receivable	5,889	**5,889**

	Unrestricted funds 2024 €	Total funds 2024 €
Subscriptions receivable	5,745	5,745

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

4. INCOME FROM CHARITABLE ACTIVITIES

	Unrestricted funds 2025 €	Total funds 2025 €
Royalties receivable	5,802,586	**5,802,586**

	Unrestricted funds 2024 €	Total funds 2024 €
Royalties receivable	5,507,000	5,507,000

5. INVESTMENT INCOME

	Unrestricted funds 2025 €	Total funds 2025 €
Franked investment income - dividends	1,253,244	**1,253,244**
Interest received	783,184	**783,184**
TOTAL 2025	2,036,428	**2,036,428**

	Unrestricted funds 2024 €	Total funds 2024 €
Franked investment income - dividends	1,220,961	1,220,961
Interest received	696,959	696,959
TOTAL 2024	1,917,920	1,917,920

Investment income from UK investment assets was €448,014 (2024: €421,942). Investment income from investment assets outside the UK was €1,588,414 (2024: €1,495,978).

6. OTHER INCOMING RESOURCES

	Unrestricted funds 2025 €	Total funds 2025 €
Other income	64,680	**64,680**

Other incoming resources comprise recharges on editorial activities.

	Unrestricted funds 2024 €	Total funds 2024 €
Other income	32,868	32,868

7. INVESTMENT MANAGEMENT COSTS

	Unrestricted funds 2025 €	Total funds 2025 €
Portfolio management	499,161	**499,161**

J.P. Morgan Private Bank, the Company's investment manager, holds a charge over the Company's cash and investments it manages on behalf of the Company.

	Unrestricted funds 2024 €	Total funds 2024 €
Portfolio management	424,572	424,572

8. ANALYSIS OF EXPENDITURE BY ACTIVITIES

	Activities undertaken directly 2025 €	Grant funding of activities (note 9) 2025 €	Support and governance costs 2025 €	Total funds 2025 €
Journals	278,326	-	1,618,636	**1,896,962**
Congress	371,758	263,274	247,611	**882,643**
Fellowships	-	1,342,051	158,846	**1,500,897**
Advanced courses	-	440,738	184,234	**624,972**
Other	42,893	334,130	132,286	**509,309**
	692,977	2,380,193	2,341,613	**5,414,783**

8. ANALYSIS OF EXPENDITURE BY ACTIVITIES (CONTINUED)

	Activities undertaken directly 2024 €	Grant funding of activities (note 9) 2024 €	Support and governance costs 2024 €	Total funds 2024 €
Journals	310,956	-	1,289,984	1,600,940
Congress	211,671	372,297	118,934	702,902
Fellowships	-	1,100,210	127,426	1,227,636
Advanced courses	-	409,362	201,593	610,955
Other	160,968	171,153	289,298	621,419
	683,595	2,053,022	2,027,235	4,763,852

ANALYSIS OF DIRECT COSTS

	Journals 2025 €	**Congress 2025 €**	**Other 2025 €**	**Total funds 2025 €**
Editorial fees and expenses	278,326	-	-	**278,326**
Women in science events	-	15,476	-	**15,476**
Education, fellowship and advanced courses committee events	-	14,363	34,743	**49,106**
National lecture expenses	-	-	1,998	**1,998**
Expenses and publicity at other conferences	-	-	670	**670**
World Wide lecture expenses	-	-	2,162	**2,162**
FEBS Congress	-	191,844	-	**191,844**
FEBS Young Scientists forum congress	-	143,387	-	**143,387**
CYSC events	-	-	3,320	**3,320**
Spinzl scheme	-	6,688	-	**6,688**
	278,326	371,758	42,893	**692,977**

8. ANALYSIS OF EXPENDITURE BY ACTIVITIES (CONTINUED)

ANALYSIS OF DIRECT COSTS (continued)

	Journals 2024 €	Congress 2024 €	Other 2024 €	Total funds 2024 €
Editorial fees and expenses	310,956	-	-	310,956
Women in science events	-	17,603	-	17,603
Education, fellowship and advanced courses committee events	-	6,198	76,978	83,176
Science and Society events	-	-	3,738	3,738
National lecture expenses	-	-	3,044	3,044
Expenses and publicity at other conferences	-	-	1,000	1,000
World Wide lecture expenses	-	-	6,858	6,858
FEBS Congress	-	155,444	-	155,444
FEBS Young Scientists forum congress	-	24,985	-	24,985
CYSC events	-	-	69,350	69,350
Spinzl scheme	-	7,441	-	7,441
	310,956	211,671	160,968	683,595

ANALYSIS OF SUPPORT COSTS

	Journals 2025 €	**Congress 2025 €**	**Fellowships 2025 €**	**Advanced courses 2025 €**
Editorial fees and expenses	1,374,409	-	-	-
HR and communications	125,659	83,575	41,869	41,869
Finance and governance	185,824	156,349	95,932	95,932
IT & website	2,989	-	184	184
Education, fellowship and advanced courses committee events	17,190	65,974	79,148	104,536
Foreign exchange gains	(87,435)	(58,287)	(58,287)	(58,287)
	1,618,636	247,611	158,846	184,234

8. ANALYSIS OF EXPENDITURE BY ACTIVITIES (CONTINUED)

ANALYSIS OF SUPPORT COSTS (continued)

	Other 2025 €	Total funds 2025 €
Editorial fees and expenses	-	**1,374,409**
HR and communications	20,908	**313,880**
Finance and governance	69,792	**603,829**
IT & website	1,241	**4,598**
Education, fellowship and advanced courses committee events	69,486	**336,334**
Foreign exchange gains	(29,141)	**(291,437)**
	132,286	**2,341,613**

	Journals 2024 €	Congress 2024 €	Fellowships 2024 €	Advanced courses 2024 €
Editorial fees and expenses	1,375,100	-	-	-
HR and communications	44,088	73,306	7,245	72,833
Finance and governance	122,450	96,017	74,591	85,898
IT & website	1,756	293	293	293
Education, fellowship and advanced courses committee events	-	-	70,638	67,910
Foreign exchange gains	(253,410)	(50,682)	(25,341)	(25,341)
	1,289,984	118,934	127,426	201,593

8. ANALYSIS OF EXPENDITURE BY ACTIVITIES (CONTINUED)

ANALYSIS OF SUPPORT COSTS (continued)

	Other 2024 €	Total funds 2024 €
Editorial fees and expenses	-	1,375,100
HR and communications	162,432	359,904
Finance and governance	275,690	654,646
IT & website	3,221	5,856
Education, fellowship and advanced courses committee events	-	138,548
Foreign exchange gains	(152,045)	(506,819)
	289,298	2,027,235

9. ANALYSIS OF GRANTS

	Grants to Institutions 2025 €	**Grants to Individuals 2025 €**	**Total funds 2025 €**
Congress	85,000	178,274	**263,274**
Fellowships	-	1,342,051	**1,342,051**
Advanced courses	375,869	64,869	**440,738**
Other	46,204	287,926	**334,130**
TOTAL 2025	507,073	1,873,120	**2,380,193**

9. ANALYSIS OF GRANTS (CONTINUED)

	Grants to Institutions 2024 €	Grants to Individuals 2024 €	Total funds 2024 €
Congress	90,004	282,293	372,297
Fellowships	-	1,100,210	1,100,210
Advanced courses	359,416	49,946	409,362
Other	56,301	114,852	171,153
TOTAL 2024	505,721	1,547,301	2,053,022

The Company has made the following material grants to institutions during the year:

	2025 €	2024 €
NAME OF INSTITUTION		
Advanced courses	**375,869**	359,416
FEBS Congress Grant	**85,000**	90,004
FEBS3+ Grant	**40,204**	19,698
Alliance for Biomedical Research Grant	**6,000**	12,000
Grants 60 Anniversary	**-**	24,603
	507,073	505,721

10. AUDITORS' REMUNERATION

The auditors' remuneration amounts to an auditor fee of €21,215 (2024 - €22,364).

11. STAFF COSTS, KEY MANAGEMENT PERSONNEL AND TRUSTEES' REMUNERATION AND EXPENSES

	2025	2024
	€	€
Wages and salaries	**1,534,841**	1,347,591
Social security costs	**268,713**	227,473
Other pension costs	**125,537**	123,575
	1,929,091	1,698,639

The average number of persons employed by the Company during the year was as follows:

	2025	2024
	€	€
Publications (Cambridge, UK)	**8**	9
Publications (Heidelberg, Germany)	**6**	6
Publications (Barcelona, Spain)	**2**	2
Treasury (Cambridge, UK)	**3**	3
Central admin (Cambridge, UK)	**2**	2
Central admin (Spain)	**1**	2
Strategic Priorities and Marketing (Greece)	**3**	1
Network (Cambridge, UK)	**1**	-
	26	25

During the year, one employee received a termination payment of €5,962 as part of a restructuring.

Three employees received remuneration falling within the band €70,000 to €79,999.

The key management personnel of the Company comprises the Trustees. The Trustees all give their time and expertise without any kind of remuneration or other benefit in kind with the exception of the following Trustees who provided services to the Company during the year:

	2025	2024
	€	€
M De La Rosa (Editorial services)	**32,216**	32,216
F Michelangeli (Editorial Services)	**66**	-
	32,282	32,216

These services are in accordance with the Company's governing document and in accordance with sections 185 to 188 of the Charities Act 2011.

During the year, 13 (2024: 12) Trustees received reimbursement of expenses or had expenses paid directly to a third party on their behalf totalling €51,191 (2024: €97,806).

Other personnel costs

Due to the wide geographical spread of the Company's activities, some staffing requirements are fulfilled by independent parties and freelancers. Details of the cost and number of personnel contracted in this manner are detailed below

	2025	2024
	€	€
Excellence Awards and Fellowships Committee Administrator	**33,800**	32,496
Advanced Courses Administrator	**-**	30,000
	33,800	62,496

The average number of other such personnel (including part-time personnel) engaged by the Company during the period was as follows:

	2025	2024
	€	€
Fellowship Committee Administrator	**1**	1
Advanced Courses Committee Administrator	**-**	1
	1	2

12. TANGIBLE FIXED ASSETS

	Leasehold improvements €	Fixtures and fittings €	Computer equipment and website €	Total €
COST				
At 1 January 2025	**23,671**	**16,274**	**92,429**	**132,374**
At 31 December 2025	**23,671**	**16,274**	**92,429**	**132,374**
DEPRECIATION				
At 1 January 2025	**2,856**	**7,302**	**85,238**	**95,396**
Charge for the year	**4,896**	**1,346**	**1,798**	**8,040**
At 31 December 2025	**7,752**	**8,648**	**87,036**	**103,436**
NET BOOK VALUE				
At 31 December 2025	**15,919**	**7,626**	**5,393**	**28,938**
At 31 December 2024	20,815	8,972	7,191	36,978

13. FIXED ASSET INVESTMENTS

	Listed investments €	Cash held at broker €	Total €
VALUATION			
At 1 January 2025	**105,287,668**	**966,053**	**106,253,721**
Additions	**43,877,856**	**-**	**43,877,856**
Disposals (proceeds €42,810,170; realised loss €81,847)	**(42,892,017)**	**-**	**(42,892,017)**
Revaluations	**1,447,797**	**-**	**1,447,797**
Cash movements	**-**	**434,126**	**434,126**
AT 31 DECEMBER 2025	**107,721,304**	**1,400,179**	**109,121,483**

13. FIXED ASSET INVESTMENTS (CONTINUED)

The market value of investment assets in the UK is €14,025,004 (2024: €15,455,828). The market value of investment assets outside the UK is €93,696,300 (2024: €89,831,840).

FEBS seeks to produce the best financial return within an acceptable level of risk. The investments are to enable FEBS to fund its activities in the long-term. The returns on investment are to provide funding of charitable activities and to increase the size of the investment fund in the next 7 – 8 years. The aim is to increase the size of the investment fund to provide higher income in the future to offset any potential reduction in income from royalties. The investment objective is to generate a return of HICP plus 3.5%, over the long term, after expenses. HICP the Harmonised Index of Consumer Prices is to be used as a measure. This should allow FEBS to at least maintain the real value of the assets, whilst funding annual expenditure over time. FEBS has a target level of investment that will cover any shortfall from publications income. FEBS uses a total return investment strategy.

The total net gains on investments as per the Statement of Financial Activities comprises a realised loss of €81,847 (2024: gain of €348,263) and unrealised gains of €1,447,797 (2024: €10,947,705).

14. DEBTORS

	2025	2024
	€	€
Trade debtors	**190,309**	131,945
Other debtors	**49,264**	51,057
Prepayments and accrued income	**1,544,325**	1,464,966
	1,783,898	1,647,968

15. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2025	2024
	€	€
Trade creditors	**22,195**	217,415
Other taxation and social security	**227,811**	229,240
Other creditors	**-**	1,239
Accruals and deferred income	**205,221**	196,808
	455,227	644,702

16. STATEMENT OF FUNDS

STATEMENT OF FUNDS - CURRENT YEAR

	Balance at 1 January 2025	**Income**	**Expenditure**	**Gains/ (Losses)**	**Balance at 31 December 2025**
	€	**€**	**€**	**€**	**€**
UNRESTRICTED FUNDS					
General Funds	**112,728,488**	**7,909,583**	**(6,630,538)**	**2,082,544**	**116,090,077**

STATEMENT OF FUNDS - PRIOR YEAR

	Balance at 1 January 2024	Income	Expenditure	Gains/ (Losses)	Balance at 31 December 2024
	€	€	€	€	€
UNRESTRICTED FUNDS					
General Funds	99,157,411	7,463,533	(5,188,424)	11,295,968	112,728,488

17. ANALYSIS OF NET ASSETS BETWEEN FUNDS

ANALYSIS OF NET ASSETS BETWEEN FUNDS - CURRENT YEAR

	Unrestricted funds 2025 €	Total funds 2025 €
Tangible fixed assets	28,938	**28,938**
Fixed asset investments	109,121,483	**109,121,483**
Current assets	7,394,883	**7,394,883**
Creditors due within one year	(455,227)	**(455,227)**
TOTAL	116,090,077	**116,090,077**

ANALYSIS OF NET ASSETS BETWEEN FUNDS - PRIOR YEAR

	Unrestricted funds 2024 €	Total funds 2024 €
Tangible fixed assets	36,978	36,978
Fixed asset investments	106,253,721	106,253,721
Current assets	7,082,491	7,082,491
Creditors due within one year	(644,702)	(644,702)
TOTAL	112,728,488	112,728,488

18. RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2025 €	2024 €
Net income for the year (as per Statement of Financial Activities)	**3,361,589**	13,571,077
ADJUSTMENTS FOR:		
Depreciation charges	**8,040**	6,446
Gains on investments	**(1,365,950)**	(11,295,968)
Dividends, interests and rents from investments	**(2,036,428)**	(1,917,920)
Loss on the sale of fixed assets	**-**	34,056
Increase in debtors	**(135,930)**	(1,171,525)
Decrease in creditors	**(189,475)**	(156,879)
NET CASH USED IN OPERATING ACTIVITIES	**(358,154)**	(930,713)

19. ANALYSIS OF CASH AND CASH EQUIVALENTS

	2025 €	2024 €
Cash in hand	**5,610,985**	5,434,523

20. ANALYSIS OF CHANGES IN NET DEBT

	At 1 January 2025 €	Cash flows €	At 31 December 2025 €
Cash at bank and in hand	**5,434,523**	**176,462**	**5,610,985**
	5,434,523	**176,462**	**5,610,985**

21. OPERATING LEASE COMMITMENTS

At 31 December 2025 the Company had commitments to make future minimum lease payments under non-cancellable operating leases as follows:

	2025	2024
	€	€
Office accommodation		
Not later than 1 year	**51,596**	54,389
Later than 1 year and not later than 5 years	**17,199**	72,519
	68,795	126,908

22. RELATED PARTY TRANSACTIONS

The Charity has not entered into any related party transactions during the year, nor are there any outstanding balances owing between related parties and the Charity at 31 December 2025 (2024: no related party transactions or balances).

2025_TrusteesReport_FinancialStatements

Final Audit Report 2026-09-10

Created:	2026-09-09
By:	Barbara Baron (baron@febs.org)
Status:	Signed
Transaction ID:	CBJCHBCAABAAEEBF5RIR7Y3EbbkjBVPyP_xAf_72RHWW

"2025_TrusteesReport_FinancialStatements" History

Document created by Barbara Baron (baron@febs.org)
2026-09-09 - 2:16:52 PM GMT

Document emailed to Prof. M De la Rosa (marosa@us.es) for signature
2026-09-09 - 2:17:01 PM GMT

Document emailed to Prof. F Michelangeli (f.michelangeli@chester.ac.uk) for signature
2026-09-09 - 2:17:01 PM GMT

Document emailed to Mr M Murray (mmurray@hillwooldridge.co.uk) for signature
2026-09-09 - 2:17:01 PM GMT

Email viewed by Prof. F Michelangeli (f.michelangeli@chester.ac.uk)
2026-09-09 - 5:30:15 PM GMT

Document e-signed by Prof. F Michelangeli (f.michelangeli@chester.ac.uk)
Signature Date: 2026-09-09 - 5:30:40 PM GMT - Time Source: server - Signature Appearance Selected: IMAGE

Email viewed by Prof. M De la Rosa (marosa@us.es)
2026-09-10 - 7:22:07 AM GMT

Document e-signed by Prof. M De la Rosa (marosa@us.es)
Signature Date: 2026-09-10 - 7:36:15 AM GMT - Time Source: server - Signature Appearance Selected: IMAGE

Email viewed by Mr M Murray (mmurray@hillwooldridge.co.uk)
2026-09-10 - 10:25:17 AM GMT

Document e-signed by Mr M Murray (mmurray@hillwooldridge.co.uk)
Signature Date: 2026-09-10 - 10:26:50 AM GMT - Time Source: server - Signature Appearance Selected: IMAGE

Agreement completed.
2026-09-10 - 10:26:50 AM GMT

Adobe Acrobat Sign